Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

3yrs ago Private Equity privateequitywire Views: 492

Levine Leichtman Capital Partners acquires Triskelion

Submitted 26/10/2020 - 9:25am

Global private equity firm Levine Leichtman Capital Partners (LLCP) has acquired Ducares (Triskelion) from First Dutch Innovations (FDI).

Triskelion, operating under the trade names Triskelion and Ducares, is a specialised provider of high-end food & feed testing services, complemented by compliance & risk management services. The Company's service offerings span a broad range of niche capabilities including nutrient, residue, bio- and genetically modified organisms (GMO) analyses. From its centrally located and state-of-the-art laboratory headquarters in Utrecht, the Company is well-positioned to support clients with high-end, innovative testing and consultancy services.

 
Robert-Jan Raterink, Managing Director of Triskelion, says: "We believe that LLCP is optimally positioned to help us further build the Company. We are excited to join LLCP's global network and believe that their strategic expertise and M&A capabilities will help us develop further as a high-end niche platform, supporting us in continuing to provide our customers with the services and quality we are reputed for."
 
Wouter Snoeijers, Managing Director at LLCP, says: "We are very excited to announce this partnership with the Triskelion team and see a substantial opportunity to contribute to its continued success. We believe that Triskelion is uniquely positioned in its end markets and are excited to support the various growth initiatives. We look forward to working with Robert-Jan and his outstanding team of highly qualified employees on the next chapter of the Company's journey."
 
Triskelion will be the second investment from Levine Leichtman Capital Partners Europe II, SCSp.
 
LLCP was advised by KPMG (commercial, financial and tax), NautaDutilh (legal) and CFI (M&A).
 
FDI was advised by PwC (M&A), Allen & Overy and CorporateWise (legal).
 

Tags Deals & Transactions Acquisitions

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.